Skip to main content

Advertisement

Table 2 Biomarker expression among screening-detected cancers (n = 1,297) and distinct categories of interval cancers (n = 948)

From: Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain

  Screening-detected cancers True interval cancers False negatives Minimal-sign cancers Occult tumors  
  n = 1,297 n = 455 n = 224 n = 166 n = 103 P-value
Estrogen receptor 1022 (82.5)* 283 (63.2 )* 178 (81.7) 114 (71.3) 84 (88.4) <0.001
 Missing values 58 7 6 6 8  
Progesterone receptor 775 (63.7)* 214 (48.2)* 128 (59.0) 86 (54.4) 60 (64.5) <0.001
 Missing values 81 11 7 8 10  
HER2 203 (21.9) 113 (29.1)* 44 (24.0) 31 (23.1) 11 (14.1) 0.018
 Missing values 371 67 41 32 25  
p53 149 (22.7) 86 (36.6)* 23 (21.5) 27 (34.6) 17 (28.8) <0.001
 Missing values 641 228 117 88 44  
Ki67 381 (40.2) 169 (52.5 )* 83 (50.3) 50 (41.7) 26 (39.4) 0.001
 Missing values 349 133 59 46 37  
  1. Number of cases and percentage of tumors with positive biomarker expression. *Standardized Pearson residuals with statistically significant deviation between observed and expected values. P-values for comparison of characteristics among the five study groups were obtained by two-sided Chi-square test. HER2, human epidermal growth factor receptor 2.